Literature DB >> 291905

Studies of binding of prekallikrein and Factor XI to high molecular weight kininogen and its light chain.

R E Thompson, R Mandle, A P Kaplan.   

Abstract

Prekallikrein and Factor XI have been reported to circulate as complexes with the coagulation cofactor high molecular weight (HMW)-kininogen. In this study we have shown that native HMW-kininogen possesses a strong binding site for prekallikrein and Factor XI with association constants of 3.4 x 10(7) M-1 and 4.2 x 10(8) M-1, respectively. The diminished binding of prekallikrein relative to Factor XI may, in part, account for the ability of kallikrein to leave the surface and interact with other molecules of Hageman factor and HMW-kininogen. Prekallikrein and Factor XI appear to compete for binding to HMW-kininogen, suggesting a single (or closely overlapping) binding site(s). The purified light chain derived from kinin-free HMW-kininogen is shown to compete with native MHW-kininogen for binding to Hageman factor substrates and direct binding of the isolated light chain to prekalikrein and Factor XI is demonstrated. This binding of the light chain to prekallikrein and Factor XI appears to be essential to the function of HMW-kininogen as a coagulation cofactor and further digestion of the light chain with excess kallikrein destroys its coagulant activity.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 291905      PMCID: PMC413037          DOI: 10.1073/pnas.76.10.4862

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  17 in total

1.  The partial thromboplastin time with kaolin. A simple screening test for first stage plasma clotting factor deficiencies.

Authors:  R R PROCTOR; S I RAPAPORT
Journal:  Am J Clin Pathol       Date:  1961-09       Impact factor: 2.493

2.  Activation and function of human Hageman factor. The role of high molecular weight kininogen and prekallikrein.

Authors:  H L Meier; J V Pierce; R W Colman; A P Kaplan
Journal:  J Clin Invest       Date:  1977-07       Impact factor: 14.808

3.  Interaction between factor XII (Hageman factor), high molecular weight kininogen and prekallikrein.

Authors:  J Y Chan; F M Habal; C E Burrowes; H Z Movat
Journal:  Thromb Res       Date:  1976-11       Impact factor: 3.944

4.  Association of factor XI and high molecular weight kininogen in human plasma.

Authors:  R E Thompson; R Mandle; A P Kaplan
Journal:  J Clin Invest       Date:  1977-12       Impact factor: 14.808

5.  Studies on human kininogens. I. Isolation, characterization, and cleavage by plasma kallikrein of high molecular weight (HMW)-kininogen.

Authors:  T Nakayasu; S Nagasawa
Journal:  J Biochem       Date:  1979-01       Impact factor: 3.387

6.  Hageman factor substrates. Human plasma prekallikrein: mechanism of activation by Hageman factor and participation in hageman factor-dependent fibrinolysis.

Authors:  R Mandle; A P Kaplan
Journal:  J Biol Chem       Date:  1977-09-10       Impact factor: 5.157

7.  Role of high-molecular-weight kininogen in surface-binding and activation of coagulation Factor XI and prekallikrein.

Authors:  R C Wiggins; B N Bouma; C G Cochrane; J H Griffin
Journal:  Proc Natl Acad Sci U S A       Date:  1977-10       Impact factor: 11.205

8.  Identification of prekallikrein and high-molecular-weight kininogen as a complex in human plasma.

Authors:  R J Mandle; R W Colman; A P Kaplan
Journal:  Proc Natl Acad Sci U S A       Date:  1976-11       Impact factor: 11.205

9.  Characterization of human high molecular weight kininogen. Procoagulant activity associated with the light chain of kinin-free high molecular weight kininogen.

Authors:  R E Thompson; R Mandle; A P Kaplan
Journal:  J Exp Med       Date:  1978-02-01       Impact factor: 14.307

10.  Relation between structure and correcting activity of bovine high molecular weight kininogen upon the clotting time of Fitzgerald-trait plasma.

Authors:  A G Scicli; R Waldmann; J A Guimaraes; G Scicli; O A Carretero; H Kato; Y N Han; S Iwanaga
Journal:  J Exp Med       Date:  1979-04-01       Impact factor: 14.307

View more
  27 in total

Review 1.  Bradykinin formation. Plasma and tissue pathways and cellular interactions.

Authors:  A P Kaplan; K Joseph; Y Shibayama; Y Nakazawa; B Ghebrehiwet; S Reddigari; M Silverberg
Journal:  Clin Rev Allergy Immunol       Date:  1998       Impact factor: 8.667

Review 2.  Factor XI and contact activation as targets for antithrombotic therapy.

Authors:  D Gailani; C E Bane; A Gruber
Journal:  J Thromb Haemost       Date:  2015-06-16       Impact factor: 5.824

3.  The evolution of factor XI and the kallikrein-kinin system.

Authors:  Michał B Ponczek; Aleksandr Shamanaev; Alec LaPlace; S Kent Dickeson; Priyanka Srivastava; Mao-Fu Sun; Andras Gruber; Christian Kastrup; Jonas Emsley; David Gailani
Journal:  Blood Adv       Date:  2020-12-22

4.  Activated factor V is a cofactor for the activation of factor XI by thrombin in plasma.

Authors:  Coen Maas; Joost C M Meijers; J Arnoud Marquart; Kamran Bakhtiari; Cees Weeterings; Philip G de Groot; Rolf T Urbanus
Journal:  Proc Natl Acad Sci U S A       Date:  2010-05-03       Impact factor: 11.205

Review 5.  Surface-mediated defense reactions. The plasma contact activation system.

Authors:  R W Colman
Journal:  J Clin Invest       Date:  1984-05       Impact factor: 14.808

6.  Human neutrophils contain and bind high molecular weight kininogen.

Authors:  E J Gustafson; A H Schmaier; Y T Wachtfogel; N Kaufman; U Kucich; R W Colman
Journal:  J Clin Invest       Date:  1989-07       Impact factor: 14.808

7.  Solution phase conformation studies of the prekallikrein binding domain of high molecular weight kininogen.

Authors:  J N Scarsdale; R B Harris
Journal:  J Protein Chem       Date:  1990-10

8.  A putative transmembrane protein with histidine-rich charge clusters encoded in the H-2K/tw5 region of mice.

Authors:  B St-Jacques; T H Han; A MacMurray; H S Shin
Journal:  Mol Cell Biol       Date:  1990-01       Impact factor: 4.272

9.  Acquired antibody to factor XI in a patient with congenital factor XI deficiency.

Authors:  D M Stern; H L Nossel; J Owen
Journal:  J Clin Invest       Date:  1982-06       Impact factor: 14.808

10.  Cleavage of human high molecular weight kininogen markedly enhances its coagulant activity. Evidence that this molecule exists as a procofactor.

Authors:  C F Scott; L D Silver; M Schapira; R W Colman
Journal:  J Clin Invest       Date:  1984-04       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.